BR9609716A - Receptores solúveis de linfotoxina-beta receptor anti-linfotoxina e anticorpos ligantes como agentes terapéuticos para tratamento de doença imunológica - Google Patents

Receptores solúveis de linfotoxina-beta receptor anti-linfotoxina e anticorpos ligantes como agentes terapéuticos para tratamento de doença imunológica

Info

Publication number: BR9609716A
Authority: BR; Brazil
Prior art keywords: lymphotoxin; receptor; treatment; therapeutic agents; blocking agents
Prior art date: 1995-07-21

Application number

BR9609716A

Other languages

English (en)

Inventor

Christopher D Benjamin

Jeffrey L Browning

Paula S Hochman

Original Assignee

Biogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-21

Filing date

1996-07-19

Publication date

1999-07-06

1996-07-19 Application filed by Biogen Inc filed Critical Biogen Inc

1999-07-06 Publication of BR9609716A publication Critical patent/BR9609716A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/143—Lymphotoxin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Cell Biology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Virology (AREA)

BR9609716A 1995-07-21 1996-07-19 Receptores solúveis de linfotoxina-beta receptor anti-linfotoxina e anticorpos ligantes como agentes terapéuticos para tratamento de doença imunológica BR9609716A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/505,606 US5925351A (en)	1995-07-21	1995-07-21	Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
PCT/US1996/012010 WO1997003687A1 (en)	1995-07-21	1996-07-19	SOLUBLE LYMPHOTOXIN-β RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES, AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASE

Publications (1)

Publication Number	Publication Date
BR9609716A true BR9609716A (pt)	1999-07-06

Family

ID=24011046

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9609716A BR9609716A (pt)	1995-07-21	1996-07-19	Receptores solúveis de linfotoxina-beta receptor anti-linfotoxina e anticorpos ligantes como agentes terapéuticos para tratamento de doença imunológica

Country Status (28)

Country	Link
US (6)	US5925351A (pt)
EP (2)	EP0840616B1 (pt)
JP (3)	JP4174563B2 (pt)
KR (2)	KR100557258B1 (pt)
CN (3)	CN1895670A (pt)
AT (1)	ATE279205T1 (pt)
AU (1)	AU715407B2 (pt)
BG (1)	BG63330B1 (pt)
BR (1)	BR9609716A (pt)
CA (1)	CA2227477A1 (pt)
CZ (1)	CZ298277B6 (pt)
DE (1)	DE69633624T2 (pt)
DK (1)	DK0840616T3 (pt)
EA (3)	EA001200B1 (pt)
EE (1)	EE04419B1 (pt)
ES (1)	ES2225889T3 (pt)
FI (1)	FI980122L (pt)
HU (1)	HU227508B1 (pt)
MX (1)	MX9800624A (pt)
NO (2)	NO327163B1 (pt)
NZ (2)	NZ503818A (pt)
PL (1)	PL186911B1 (pt)
PT (1)	PT840616E (pt)
RO (1)	RO121799B1 (pt)
SI (1)	SI0840616T1 (pt)
SK (1)	SK286409B6 (pt)
TR (1)	TR199800091T1 (pt)
WO (1)	WO1997003687A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5925351A (en) *	1995-07-21	1999-07-20	Biogen, Inc.	Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
IL129527A (en) *	1996-10-25	2006-12-10	Biogen Idec Inc	Pharmaceutical preparations containing soluble lymphoxine-beta receptors
SI0954333T1 (sl) *	1996-10-25	2006-12-31	Biogen Idec Inc	Topni limfotoksin-beta receptorji, anti-limfotoksin receptorska protitelesa in anti-limfotoksin ligandna protitelesa kot terapevtska sredstva za zdravljenje imunoloskih bolezni
US7255854B1 (en) *	1996-10-25	2007-08-14	Biogen, Inc.	Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
EE9900492A (et) *	1997-04-18	2000-06-15	Biogen, Incorporated	II tüüpi TGF-ß retseptori/immunoglobuliini konstantse piirkonna hübriidvalgud
US7118742B2 (en) *	1997-07-07	2006-10-10	La Jolla Institute For Allergy And Immunology	Ligand for herpes simplex virus entry mediator and methods of use
KR100622960B1 (ko) *	1998-01-30	2006-09-12	바이오겐 아이덱 엠에이 인코포레이티드	림프독소（ｌｔ）경로 저해제를 사용한 여포 림프종의 치료 방법
US7060667B1 (en) *	1998-01-30	2006-06-13	Biogen Idec Ma, Inc.	Treatment of follicular lymphomas using inhibitors of the LT pathway
WO2000021558A1 (en) *	1998-10-09	2000-04-20	Biogen, Inc.	Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) *	1998-12-17	2007-04-24	Biogen Idec Ma Inc.	Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
JP3822822B2 (ja) *	1999-06-28	2006-09-20	ビーエーエスエフアクチェンゲゼルシャフト	腫瘍の成長を予防する方法
US6346247B1 (en)	1999-10-28	2002-02-12	Promega Corporation	Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
HUP0302573A2 (hu) *	2000-10-13	2003-10-28	Biogen, Inc.	Humanizált anti-LT-béta-R ellenanyagok
MXPA03005036A (es) *	2000-12-07	2003-09-05	Lilly Co Eli	Proteinas de fusion glp-1.
WO2002083162A1 (en) *	2001-04-13	2002-10-24	University Of Chicago	Use of a cd8+ t cell inhibitory agent in the presence of a cd4+ t cell inhibitory agent for inhibition of transplant rejection
US7265208B2 (en) *	2001-05-01	2007-09-04	The Regents Of The University Of California	Fusion molecules and treatment of IgE-mediated allergic diseases
WO2003011322A1 (en) *	2001-08-02	2003-02-13	Genset S.A.	Agonists and antagonists of genoxin for use in the treatment of metabolic disorders
EP1578920A4 (en) *	2002-02-08	2007-11-21	Wyeth Corp	COMPOSITION AND METHOD FOR MODULATING AN INFLAMMATORY REACTION
WO2004002431A2 (en) *	2002-07-01	2004-01-08	Biogen, Inc.	Humanized anti-lymphotoyin beta receptor antibodies
AU2003287431A1 (en) *	2002-10-31	2004-05-25	Biogen Idec Ma Inc.	Treatment of immunological renal disorders by lymphotoxin pathway inhibitors
WO2004058191A2 (en) *	2002-12-20	2004-07-15	Biogen Idec Ma Inc.	Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
RS20050481A (en) *	2002-12-20	2007-08-03	Biogen Idec Ma Inc.,	Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
JP5091476B2 (ja) *	2003-06-27	2012-12-05	バイオジェン・アイデック・エムエイ・インコーポレイテッド	均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
EP1699486A4 (en) *	2003-12-08	2007-07-18	Centocor Inc	ANTI-LYMPHOTOXIN HUMAN ALPHA ANTIBODIES, COMPOSITIONS, METHODS AND USES
NZ550518A (en) *	2004-03-23	2009-11-27	Biogen Idec Inc	Agents that cross link TNF receptors for treating cancer
AU2005271403A1 (en) *	2004-08-03	2006-02-16	Biorexis Pharmaceutical Corporation	Combination therapy using transferrin fusion proteins comprising GLP-1
WO2006074399A2 (en) *	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	Multispecific binding molecules comprising connecting peptides
WO2006135660A2 (en) *	2005-06-10	2006-12-21	University Of Chicago	Therapies involving lymphotoxin beta receptor
JP2009510172A (ja) *	2005-10-04	2009-03-12	ジョンズホプキンスユニバーシティ	炎症を処置するための組成物および方法
WO2007109733A2 (en)	2006-03-21	2007-09-27	The Johns Hopkins University	Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
CN101511868B (zh)	2006-07-24	2013-03-06	比奥雷克西斯制药公司	毒蜥外泌肽融合蛋白
RU2486201C2 (ru)	2006-10-12	2013-06-27	Дженентек, Инк.	Антитела к лимфотоксину-альфа
US8338376B2 (en) *	2006-10-20	2012-12-25	Biogen Idec Ma Inc.	Compositions comprising variant LT-B-R-IG fusion proteins
NZ576424A (en) *	2006-10-20	2012-09-28	Biogen Idec Inc	Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
EP3181580A1 (en)	2006-11-02	2017-06-21	Acceleron Pharma Inc.	Alk1 receptor and ligand antagonists and uses thereof
WO2008083169A2 (en) *	2006-12-26	2008-07-10	The Johns Hopkins University	Compositions and methods for the treatment of immunologic disorders
CA2680792A1 (en) *	2007-03-15	2008-09-18	Biogen Idec Ma Inc.	Treatment of autoimmune disorders
EP2167687B1 (en)	2007-06-08	2013-03-27	Biogen Idec MA Inc.	Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
AU2009334498A1 (en) *	2008-12-31	2011-07-21	Biogen Idec Ma Inc.	Anti-lymphotoxin antibodies
CA2988299C (en)	2015-06-05	2023-10-31	Ibio, Inc.	Endostatin fragments and variants for use in treating fibrosis
WO2019238966A1 (en) *	2018-06-15	2019-12-19	Universität Bern	LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
EP3969569A1 (en)	2019-05-14	2022-03-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
EP4392455A4 (en)	2021-08-25	2025-08-20	Ibio Inc	ANTI-CD-25 ANTIBODIES

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en) *	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4338397A (en) *	1980-04-11	1982-07-06	President And Fellows Of Harvard College	Mature protein synthesis
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4485045A (en) *	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4544545A (en) *	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4758549A (en) *	1983-12-13	1988-07-19	Kabushiki Kaisha Mayashibara Seibutsu Kagaku Kenkyujo	Lymphokine, monoclonal antibody specific to the lymphokine and their production and uses
NZ212207A (en) *	1984-05-31	1991-07-26	Genentech Inc	Recombinant lymphotoxin
US4959457A (en) *	1984-05-31	1990-09-25	Genentech, Inc.	Anti-lymphotoxin
GB8529014D0 (en)	1985-11-25	1986-01-02	Biogen Nv	Enhanced secretion of heterologous proteins
US4822605A (en) *	1986-02-18	1989-04-18	Exovir, Inc.	Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4849509A (en) *	1987-02-20	1989-07-18	The Wistar Institute	Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
CA2001756A1 (en)	1988-10-31	1991-04-30	Seiichi Uesugi	New human lymphotoxin n-end deletion mutant
US5225538A (en) *	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US7030080B2 (en) *	1990-06-27	2006-04-18	Biogen, Inc.	Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
EP0536299B1 (en) *	1990-06-27	2001-06-06	Biogen, Inc.	Surface complexed lymphotoxin
US5670149A (en) *	1990-06-27	1997-09-23	Biogen, Inc.	Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
DE69334224D1 (de) *	1992-12-04	2008-07-17	Biogen Idec Inc	Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
US5747023A (en)	1994-07-01	1998-05-05	Genentech, Inc.	Cancer therapy using lymphotoxin
US5876950A (en)	1995-01-26	1999-03-02	Bristol-Myers Squibb Company	Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
ATE268604T1 (de)	1995-01-26	2004-06-15	Biogen Inc	Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren
US6312691B1 (en) *	1996-01-26	2001-11-06	Jeffrey L. Browning	Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
GB9514518D0 (en)	1995-07-15	1995-09-13	Sod Conseils Rech Applic	Guanidine salt inhibitors of NO synthase and cyclooxygenase
US5925351A (en) *	1995-07-21	1999-07-20	Biogen, Inc.	Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en)	1995-07-28	2001-09-18	Northwestern University	Herpes virus entry receptor protein
IL129527A (en)	1996-10-25	2006-12-10	Biogen Idec Inc	Pharmaceutical preparations containing soluble lymphoxine-beta receptors
US7255854B1 (en) *	1996-10-25	2007-08-14	Biogen, Inc.	Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
GB9622660D0 (en)	1996-10-31	1997-01-08	Biocine Spa	Immunogenic detoxified mutant toxin
CA2229449A1 (en)	1997-04-25	1998-10-25	Takeda Chemical Industries, Ltd.	Novel receptor protein and its use
US7060667B1 (en) *	1998-01-30	2006-06-13	Biogen Idec Ma, Inc.	Treatment of follicular lymphomas using inhibitors of the LT pathway
WO2000021558A1 (en) *	1998-10-09	2000-04-20	Biogen, Inc.	Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) *	1998-12-17	2007-04-24	Biogen Idec Ma Inc.	Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
HUP0302573A2 (hu) *	2000-10-13	2003-10-28	Biogen, Inc.	Humanizált anti-LT-béta-R ellenanyagok
WO2004002431A2 (en) *	2002-07-01	2004-01-08	Biogen, Inc.	Humanized anti-lymphotoyin beta receptor antibodies
WO2004058191A2 (en) *	2002-12-20	2004-07-15	Biogen Idec Ma Inc.	Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
RS20050481A (en) *	2002-12-20	2007-08-03	Biogen Idec Ma Inc.,	Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
NZ550518A (en) *	2004-03-23	2009-11-27	Biogen Idec Inc	Agents that cross link TNF receptors for treating cancer
WO2007146414A2 (en)	2006-06-15	2007-12-21	Biogen Idec Ma Inc.	Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents

1995
- 1995-07-21 US US08/505,606 patent/US5925351A/en not_active Expired - Lifetime
1996
- 1996-07-19 EA EA199800144A patent/EA001200B1/ru not_active IP Right Cessation
- 1996-07-19 SK SK68-98A patent/SK286409B6/sk not_active IP Right Cessation
- 1996-07-19 EP EP96925393A patent/EP0840616B1/en not_active Expired - Lifetime
- 1996-07-19 MX MX9800624A patent/MX9800624A/es not_active IP Right Cessation
- 1996-07-19 ES ES96925393T patent/ES2225889T3/es not_active Expired - Lifetime
- 1996-07-19 PL PL96324622A patent/PL186911B1/pl not_active IP Right Cessation
- 1996-07-19 AU AU65912/96A patent/AU715407B2/en not_active Ceased
- 1996-07-19 EA EA200000122A patent/EA002966B1/ru not_active IP Right Cessation
- 1996-07-19 CN CNA2006101002067A patent/CN1895670A/zh active Pending
- 1996-07-19 TR TR1998/00091T patent/TR199800091T1/xx unknown
- 1996-07-19 FI FI980122A patent/FI980122L/fi not_active IP Right Cessation
- 1996-07-19 EP EP04017208A patent/EP1488799A3/en not_active Withdrawn
- 1996-07-19 CA CA002227477A patent/CA2227477A1/en not_active Abandoned
- 1996-07-19 CN CNB961967706A patent/CN1146441C/zh not_active Expired - Fee Related
- 1996-07-19 EA EA200200503A patent/EA005734B1/ru not_active IP Right Cessation
- 1996-07-19 CZ CZ0017298A patent/CZ298277B6/cs not_active IP Right Cessation
- 1996-07-19 US US09/000,166 patent/US6403087B1/en not_active Expired - Lifetime
- 1996-07-19 RO RO98-00101A patent/RO121799B1/ro unknown
- 1996-07-19 KR KR1020047017609A patent/KR100557258B1/ko not_active Expired - Fee Related
- 1996-07-19 DE DE69633624T patent/DE69633624T2/de not_active Expired - Lifetime
- 1996-07-19 SI SI9630693T patent/SI0840616T1/xx unknown
- 1996-07-19 WO PCT/US1996/012010 patent/WO1997003687A1/en active IP Right Grant
- 1996-07-19 NZ NZ503818A patent/NZ503818A/en not_active IP Right Cessation
- 1996-07-19 AT AT96925393T patent/ATE279205T1/de active
- 1996-07-19 NZ NZ313441A patent/NZ313441A/en not_active IP Right Cessation
- 1996-07-19 EE EE9800013A patent/EE04419B1/xx not_active IP Right Cessation
- 1996-07-19 CN CNA200410007059XA patent/CN1607005A/zh active Pending
- 1996-07-19 PT PT96925393T patent/PT840616E/pt unknown
- 1996-07-19 BR BR9609716A patent/BR9609716A/pt active Search and Examination
- 1996-07-19 JP JP50691997A patent/JP4174563B2/ja not_active Expired - Fee Related
- 1996-07-19 DK DK96925393T patent/DK0840616T3/da active
- 1996-07-19 KR KR10-1998-0700464A patent/KR100493980B1/ko not_active Expired - Fee Related
- 1996-07-19 HU HU9802483A patent/HU227508B1/hu not_active IP Right Cessation
1998
- 1998-01-14 NO NO19980172A patent/NO327163B1/no not_active IP Right Cessation
- 1998-02-20 BG BG102265A patent/BG63330B1/bg unknown
1999
- 1999-04-30 US US09/303,262 patent/US6669941B1/en not_active Expired - Lifetime
2002
- 2002-02-15 US US10/077,406 patent/US7427403B2/en not_active Expired - Fee Related
2007
- 2007-06-19 JP JP2007161925A patent/JP2007254488A/ja not_active Withdrawn
- 2007-10-31 US US11/982,415 patent/US7951371B2/en not_active Expired - Fee Related
2008
- 2008-09-05 NO NO20083842A patent/NO20083842L/no not_active Application Discontinuation
2011
- 2011-02-28 US US13/037,092 patent/US8455445B2/en not_active Expired - Fee Related
- 2011-09-26 JP JP2011209921A patent/JP2012041350A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
RO121799B1 (ro)	2008-05-30
BG63330B1 (bg)	2001-10-31
KR19990035805A (ko)	1999-05-25
AU715407B2 (en)	2000-02-03
FI980122A0 (fi)	1998-01-20
KR20040107513A (ko)	2004-12-20
EP0840616B1 (en)	2004-10-13
NO20083842L (no)	1998-03-23
PL324622A1 (en)	1998-06-08
EP1488799A2 (en)	2004-12-22
DE69633624D1 (de)	2004-11-18
CZ17298A3 (cs)	1999-05-12
EE9800013A (et)	1998-06-15
JP2007254488A (ja)	2007-10-04
ES2225889T3 (es)	2005-03-16
EA200000122A1 (ru)	2000-06-26
EP0840616A1 (en)	1998-05-13
EA200200503A1 (ru)	2002-12-26
CN1895670A (zh)	2007-01-17
NO980172L (no)	1998-03-23
CA2227477A1 (en)	1997-02-06
HUP9802483A3 (en)	2004-08-30
US6403087B1 (en)	2002-06-11
TR199800091T1 (xx)	1998-04-21
SK6898A3 (en)	2000-10-09
EA199800144A1 (ru)	1998-08-27
EA001200B1 (ru)	2000-12-25
DK0840616T3 (da)	2005-01-31
SI0840616T1 (en)	2005-04-30
US20050037003A1 (en)	2005-02-17
SK286409B6 (sk)	2008-09-05
KR100493980B1 (ko)	2005-11-11
BG102265A (bg)	1998-09-30
DE69633624T2 (de)	2006-03-09
EE04419B1 (et)	2005-02-15
WO1997003687A1 (en)	1997-02-06
CN1146441C (zh)	2004-04-21
US7951371B2 (en)	2011-05-31
US5925351A (en)	1999-07-20
JP2012041350A (ja)	2012-03-01
NO980172D0 (no)	1998-01-14
PT840616E (pt)	2004-12-31
CN1195294A (zh)	1998-10-07
MX9800624A (es)	1998-04-30
ATE279205T1 (de)	2004-10-15
NO327163B1 (no)	2009-05-04
HUP9802483A2 (hu)	1999-02-01
JP4174563B2 (ja)	2008-11-05
JPH11510488A (ja)	1999-09-14
CN1607005A (zh)	2005-04-20
US20110046073A1 (en)	2011-02-24
EA002966B1 (ru)	2002-12-26
EA005734B1 (ru)	2005-06-30
PL186911B1 (pl)	2004-03-31
NZ313441A (en)	2000-07-28
NZ503818A (en)	2001-08-31
FI980122A7 (fi)	1998-03-19
EP1488799A3 (en)	2012-07-18
FI980122L (fi)	1998-03-19
US6669941B1 (en)	2003-12-30
US8455445B2 (en)	2013-06-04
CZ298277B6 (cs)	2007-08-15
HK1010832A1 (en)	1999-07-02
US7427403B2 (en)	2008-09-23
HU227508B1 (en)	2011-07-28
AU6591296A (en)	1997-02-18
US20110250200A1 (en)	2011-10-13
KR100557258B1 (ko)	2006-03-10

Publication	Publication Date	Title
BR9609716A (pt)	1999-07-06	Receptores solúveis de linfotoxina-beta receptor anti-linfotoxina e anticorpos ligantes como agentes terapéuticos para tratamento de doença imunológica
EA200100822A1 (ru)	2002-02-28	Baff, относящиеся к нему блокирующие агенты и их применение в стимуляции и ингибировании b-клеток и иммуноглобулинов в иммунных реакциях
NO982062D0 (no)	1998-05-06	Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
HUT76875A (en)	1997-12-29	Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
ATE331531T1 (de)	2006-07-15	Lösliche lymphotoxin-beta rezeptoren, anti- lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
EP0727214A3 (en)	1997-10-01	Substituted phenylpyrimidine derivatives, for the treatment or prevention of CNS diseases
DK0633931T3 (da)	2003-09-15	Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon
GR3025698T3 (en)	1998-03-31	NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.
EA199700242A1 (ru)	1998-04-30	Индазолкарбоксамиды, способ их получения, фармкомпозиция и способ ингибирования 5-нтрецептора
EA200400692A1 (ru)	2004-12-30	Антагонисты хемокинного рецептора и способы их применения
ATE100331T1 (de)	1994-02-15	Verfahren zur behandlung von septischem schock.
EP1723967A3 (en)	2007-01-10	Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
PE37398A1 (es)	1998-08-10	Composiciones para la prevencion y tratamiento de transtornos gastrointestinales
DE69001070D1 (de)	1993-04-15	Verwendung von beta-blockierungsmitteln zur behandlung der meniere-krankheit.

Legal Events

Date	Code	Title	Description
2003-01-14	EG	Technical examination (opinion): publication of technical examination (opinion)
2005-08-30	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2006-06-20	B25D	Requested change of name of applicant approved	Owner name: BIOGEN IDEC MA, INC. (US) Free format text: ALTERADO DE: BIOGEN, INC.
2006-07-04	B25D	Requested change of name of applicant approved	Owner name: BIOGEN IDEC MA INC. (US) Free format text: ALTERADA DE: BIOGEN IDEC MA, INC.
2007-04-10	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO COM BASE NOS ARTS: 8O 10(X), 11, E 13 DA LPI ,BEM COMO NO ART. 229-A DA LEI 10.196
2007-11-20	B12B	Appeal against refusal [chapter 12.2 patent gazette]
2012-02-22	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2012-11-20	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2014-04-15	B11D	Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time